Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a neuroscience-focused biopharmaceutical company that entered the public markets through a merger with ARYA Sciences Acquisition Corp, a blank-check company sponsored by Perceptive Advisors that completed its IPO in 2019. The August 2020 quarterly filing reflects the company during its de-SPAC transition period, with the business combination closing in October of that year. Cerevel's pipeline targeted central nervous system disorders including Parkinson's disease, schizophrenia, and epilepsy. The company was ultimately acquired by AbbVie in a 2024 transaction. Sign up on SpacDesk for full filings, timeline data, and sponsor analytics on Cerevel and every active SPAC in the market.